Medtronic’s IN.PACT Admiral drug-coated balloon was not linked to excess mortality after placement for peripheral artery disease (PAD) in the superficial femoral and popliteal arteries, according to 5 years of data from the device development program presented at the Leipzig Interventional Course (LINC) and to be published in the Journal of the American College of Cardiology.
Also at LINC were positive data on the Lumee Oxygen Platform, an injectable biosensor for real-time monitoring of tissue oxygen levels in PAD interventions or wound management. The Lumee was faster than tcpO2 in detecting oxygen change and was better at catching reactive hyperemia, according to a press release.
Gore launched its Fracture-Free Assurance Program — refunding Tigris vascular stents that fracture within 10 years of implantation — on the heels of a presentation at LINC showing 93% primary patency at 12 months and zero stent frame fractures among registry participants treated for PAD.
A small estimated left ventricular outflow tract (LVOT) area after transcatheter mitral valve replacement was the best predictor of LVOT obstruction afterward, researchers reported in JACC: Cardiovascular Interventions.
Fractional flow reserve-guided complete revascularization for ST-segment elevation MI led to fewer subsequent revascularizations than compared to culprit-only stenting in DANAMI-3 PRIMULTI. Now investigators report in EuroIntervention that the difference was driven by non-treated lesions, not de novo ones.
In the 10 years after patent foramen ovale closure for cryptogenic stroke, only 1% of patients had another stroke. Among patients who quit antithrombotics, ischemic events did not increase over follow-up. (Journal of the American College of Cardiology)
Endovascular stroke treatment outcomes and complications weren’t worse with M2 than with M1 occlusions in the middle cerebral artery, according to an observational analysis of the MR CLEAN registry. (Stroke)